Ripretinib, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST).
Brand name Qinlock.
An oral kinase inhibitor.
Pregnancy category AU. D-Use should be avoided.
Side effects include alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome and vomiting.
Alopecia is a unique side effect to ripretinib, which is not seen with other tyrosine kinase inhibitors.
Approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).
Serious side effects: skin cancer, hypertension and cardiac dysfunction manifested as ejection fraction decrease.
It may cause harm to a developing fetus or a newborn baby.
Approval based on randomized, double-blind, placebo-controlled clinical trial (INVICTUS that enrolled 129 participants with advanced gastrointestinal stromal tumor (GIST) who had received prior treatment with imatinib, sunitinib, and regorafenib.
Participants randomized to receive ripretinib or placebo.